Metronomic chemotherapy induces disease control in patients with advanced-stage breast cancer with a lower incidence of adverse events compared with conventional maximum tolerated dose chemotherapy
Ideal agents to be used in metronomic chemotherapy regimens should be oral, inexpensive and well-tolerated, with no or minimal cumulative toxicity
Several phase III trials on metronomic chemotherapy are ongoing and might demonstrate whether this approach will remain a niche option or assume a wider acceptance and application
Most drugs used in a metronomic fashion have generic equivalents, are inexpensive, and available in oral form, which avoids costly hospital stays and intravenous injections
Metronomic chemotherapy regimens combined with molecularly targeted agents might improve the therapeutic activity and avoid industry concerns regarding the use of off-patent or cheap chemotherapy drugs
Metronomic protocols should be guided by molecular data as the genetic and epigenetic landscape of a given tumour can be markedly different at diagnosis, post-treatment and at relapse
Over 15 years ago, low-dose metronomic chemotherapy was shown to induce disease control in patients with advanced-stage breast cancer with a lower incidence of adverse events compared with conventional maximum tolerated dose chemotherapy. Good response rates have been seen in heavily pre-treated patients for whom limited treatment options are available. Most patients prefer oral therapy and metronomic chemotherapy is a convenient alternative in patients with advanced-stage disease in which minimal toxicity and good tumour control are the overall aims of treatment. The addition of metronomic protocols to standard neoadjuvant chemotherapy regimens has produced promising pathological complete response rates. Ongoing trials including the SYSUCC-001 trial in patients with triple-negative breast cancer and the IBCSG 22-00 trial that is assessing a cyclophosphamide–methotrexate maintenance regimen after standard adjuvant therapy in hormone receptor-negative disease, will clarify the value of adding this approach to conventional therapies. The low cost associated with metronomic chemotherapy represents an opportunity for the utilization of this treatment option, especially in developing countries, and poses a challenge for the launch of large trials sponsored by industry. Using breast cancer as the principal example, we discuss the key clinical advances in this area, including new trial design, appropriate patient and end point selection, as well as the evolving rationale for metronomic chemotherapy combinations.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Human Cell Open Access 28 January 2022
Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling
Cell Death & Disease Open Access 20 April 2021
Molecular Cancer Open Access 24 August 2020
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).
Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).
Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).
Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73–80 (2002).
Orlando, L. et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 17, 961–967 (2006).
André, N., Carré, M. & Pasquier, E. Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413–431 (2014).
Simkens, L. H. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385, 1843–1852 (2015).
Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423–436 (2004).
Klement, G. L. & Kamen, B. A. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J. Pediatr. Hematol. Oncol. 33, 1–3 (2011).
Pasquier, E., Kavallaris, M. & André, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7, 455–465 (2010).
Kamen, B. A., Rubin, E., Aisner, J. & Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935–2937 (2000).
Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7, 427–436 (2001).
Rose, D. P. & Davis, T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 40, 4043–4047 (1980).
Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4, 316–314, 324 (2002).
Kummar, S. et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17, 5123–5131 (2011).
Radojcic, V. et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother. 59, 137–148 (2010).
Lake, R. A. & Robinson, B. W. Immunotherapy and chemotherapy—a practical partnership. Nat. Rev. Cancer 5, 397–405 (2005).
Tesniere, A. et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 20, 504–511 (2008).
Kaneno, R., Shurin G. V, Tourkova, I. L. & Shurin, M. R. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 7, 58 (2009).
Kaneno, R. et al. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell. Oncol. (Dordr.) 34, 97–106 (2011).
Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641–648 (2007).
Banissi, C., Ghiringhelli, F., Chen, L. & Carpentier, A. F. TREG depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58, 1627–1634 (2009).
Zhao, J. et al. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70, 4850–4858 (2010).
Kan, S. et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 32, 5363–5369 (2012).
Michels, T. et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 9, 292–300 (2012).
Sierro, S. R. et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur. J. Immunol. 41, 2217–2228 (2011).
Geary, S. M., Lemke, C. D., Lubaroff, D. M. & Salem, A. K. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE 8, e67904 (2013).
Todaro, M., Meraviglia, S., Caccamo, N., Stassi, G. & Dieli, F. Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology 2, e25821 (2013).
Lutsiak, M. E. et al. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862–2868 (2005).
Ge, Y. et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61, 353–362 (2012).
Inoue, H. & Tani, K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 21, 39–49 (2014).
Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).
Nars, M. S. & Kaneno, R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 132, 2471–2478 (2013).
Sheng Sow, H. & Mattarollo, S. R. Combining low-dose or metronomic chemotherapy with anticancer vaccines: a therapeutic opportunity for lymphomas. Oncoimmunology 2, e27058 (2013).
Weir, G. et al. Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models [abstract]. J. Immunother. Cancer 2 (Suppl. 3), P130 a2508 (2015).
Miller, K. D., Sweeney, C. J. & Sledge, G. W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195–1206 (2001).
Sweeney, C. J. et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61, 3369–3372 (2001).
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. Ecancermedicalscience 8, 1–13 (2014).
Bloom, H. J., Richardson, W. W. & Harries, E. J. Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br. Med. J. 2, 213–221 (1962).
Brunner, W. N., Stephens, R. W. & Dano, K. Control of invasion and metastasis in Diseases of the breast 4th edn (eds Harris, J. R., Lippman, M. E., Morrow, M. & Osborne, C. K.) 367–376 (Lippincott Williams and Wilkins, 2009).
Cardoso, F. et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii1–vii9 (2012).
Cardoso, F. et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur. J. Cancer. 48, 3355–3377 (2012).
Lin, N. U. et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 22, 203–210 (2013).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009).
Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).
Kontani, K. et al. Factors responsible for long-term survival in metastatic breast cancer. World J. Surg. Oncol. 12, 344 (2014).
Kontani, K. et al. Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol. Clin. Oncol. 1, 225–230 (2013).
Greenberg, P. A. et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197–2205 (1996).
Munzone, E. & Colleoni, M. The role of maintenance strategies in breast cancer. Memo 7, 52–156 (2014).
Sánchez-Muñoz, A., Pérez-Ruiz, E., Ribelles, N., Márquez, A. & Alba, E. Maintenance treatment in metastatic breast cancer. Expert Rev. Anticancer Ther. 8, 1907–1912 (2008).
Malik, P. S., Raina, V. & André, N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front. Oncol. 4, 76 (2014).
Gralow, J. R. et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J. Clin. Oncol. 26, 814–819 (2008).
Kaufmann, M. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24, 1940–1949 (2006).
Schwartz, G. F. & Hortobagyi, G. N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 100, 2512–2532 (2004).
Ebos, J. M. et al. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol. Med. 6, 1561–1576 (2014).
Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
Ebos, J. M. et al. Accelerated Metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
Ebos, J. M., Lee, C. R. & Kerbel, R. S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15, 5020–5025 (2009).
Masuda, N. et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother. Pharmacol. 74, 229–238 (2014).
Dellapasqua, S. et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 20, 319–323 (2011).
Bottini, A. et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 24, 3623–3628 (2006).
Le Deley, M.-C. et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J. Clin. Oncol. 28, 3987–3993 (2010).
Lam, T., Hetherington, J. W., Greenman, J. & Maraveyas, A. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17, 113–121 (2006).
Crivellari, D. et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a “standard chemotherapy regimen”: the CASA randomized trial. Breast 22, 130–137 (2013).
Ohashi, Y. et al. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). Breast Cancer Res. Treat. 119, 633–641 (2010).
Kasumi, F. et al. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64, 146–153 (2003).
Watanabe, T. et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J. Clin. Oncol. 27, 1368–1374 (2009).
Park, Y. et al. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage, I, II, or IIIA lymph node-positive breast cancer: a comparative study. Br. J. Cancer 101, 598–604 (2009).
Colleoni, M. et al. Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC) [abstract]. J. Clin. Oncol. 33, a1002 (2015).
Colleoni, M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17, 232–238 (2006).
Wong, N. S. et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28, 723–730 (2010).
Blum, J. L. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17, 485–493 (1999).
Zelek, L. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92, 2267–2272 (2001).
Sawada, N. et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4, 1013–1019 (1998).
Endo, M. et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer 83, 127–134 (1999).
Wang, Z. et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother. Pharmacol. 69, 515–522 (2012).
Leonard, R., Hennessy, B. T., Blum, J. L. & O'Shaughnessy, J. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin. Breast Cancer 11, 349–356 (2011).
Fedele, P. et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur. J. Cancer 48, 24–29 (2012).
Stockler, M. R. et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J. Clin. Oncol. 29, 4498–4504 (2011).
O'Brien, M. E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19, 1–7 (2008).
Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95–99 (2002).
Munzone, E. et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 19, 33–37 (2010).
Belotti, D. et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843–1849 (1996).
Hotchkiss, K. A. et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol. Cancer Ther. 1, 1191–1200 (2002).
Vacca, A. et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94, 4143–4155 (1999).
Briasoulis, E. et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13, 263 (2013).
Rajdev, L. et al. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother. Pharmacol. 68, 1119–1124 (2011).
Briasoulis, E. et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 15, 6454–6461 (2009).
Addeo, R. et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin. Breast Cancer 10, 301–306 (2010).
Saridaki, Z. et al. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 69, 35–42 (2012).
Barbolosi, D. et al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother. Pharmacol. 74, 647–652 (2014).
Addeo, R. et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother. Pharmacol. 70, 603–609 (2012).
Orlando, L. et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6, 225 (2006).
Burstein, H. J. et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study [abstract 4]. 28th Annual San Antonio Breast Cancer Symposium (2005).
Dellapasqua, S. et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26, 4899–4905 (2008).
Rochlitz, C. et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—a multicenter, randomized phase III trial [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a518 (2014).
Montagna, E. et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin. Breast Cancer 12, 207–214 (2012).
García-Sáenz, J. A., et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J. Chemother. 20, 632–639 (2008).
Teicher, B. A., Korbut, T. T., Menon, K., Holden, S. A. & Ara, G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother. Pharmacol. 33, 515–522 (1994).
Hida, T. et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6, 2006–2011 (2000).
Half, E. et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62, 1676–1681 (2002).
Cassidy, P. B., Moos, P. J., Kelly, R. C. & Fitzpatrick, F. A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 8, 846–855 (2002).
Mainetti, L. E., Rozados, V. R., Rossa, A., Bonfil, R. D. & Scharovsky, O. G. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J. Cancer Res. Clin. Oncol. 137, 151–163 (2011).
Perroud, H. A. et al. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol. 9, 451–462 (2013).
Young, S. D., Lafrenie, R. M. & Clemons, M. J. Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr. Oncol. 19, e75–e83 (2012).
Aurilio, G. et al. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: A mono-institutional case-cohort report. Breast J. 18, 470–474 (2012).
Licchetta, A. et al. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J. Chemother. 22, 201–204 (2010).
Schwartzberg, L. S. et al. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin. Breast Cancer 14, 13–19 (2014).
Soriano, J. L. et al. Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int. J. Breast Cancer 2011, 710292 (2011).
US National Library of Medicine. ClinicalTrials.gov[online], (2015).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2015).
Harris, A. L. et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin. Cancer Res. 7, 1992–1997 (2001).
Deprimo, S. E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007).
Bertolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342–4346 (2003).
Shaked, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101–111 (2005).
Shaked, Y. et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106, 3058–3061 (2005).
Mancuso, P. et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452–459 (2006).
Torrisi, R. et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br. J. Cancer 99, 1564–1571 (2008).
Murakami, H., Ogata, Y., Akagi, Y., Ishibashi, N. & Shirouzu, K. Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance. Exp. Ther. Med. 2, 595–600 (2011).
Bertolini, F., Marighetti, P. & Shaked, Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim. Biophys. Acta 1806, 131–137 (2010).
Dellapasqua, S. et al. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 21, 309–313 (2012).
Emmenegger, U. et al. Generation of a plasma microRNA (miRNA) signature predicting response to metronomic chemotherapy (MC) for advanced breast cancer (ABC) [abstract]. Ann. Oncol. 25 (Suppl. 4), 178P (2014).
Hackl, C. et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62, 259–271 (2013).
Iwamoto, H. et al. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 13, 187–197 (2011).
Le Deley, M.-C. et al. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr. Blood Cancer 45, 25–31 (2005).
De Vita, S. et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann. Hematol. 84, 760–762 (2005).
Eichhorn, M. E. et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer 126, 1235–1245 (2010).
Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63, 7400–7409 (2003).
Yu, D.-H. et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials 34, 3925–3937 (2013).
Gazdar, A. F. & Minna, J. D. Precision medicine for cancer patients: lessons learned and the path forward. J. Natl Cancer Inst. 105, 1262–1263 (2013).
Le, D. T. & Jaffee, E. M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439–3444 (2012).
Vacchelli, E. et al. Trial Watch. Oncoimmunology 3, e27878 (2014).
Cerullo, V. et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737–1746 (2011).
André, N., Banavali, S., Snihur, Y. & Pasquier, E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 14, e239–e248 (2013).
Metronomics Global Health Initiative. http://metronomics.newethicalbusiness.org/.
Montagna, E., Cancello, G., Dellapasqua, S., Munzone, E. & Colleoni, M. Metronomic therapy and breast cancer: a systematic review. Cancer Treat. Rev. 40, 942–950 (2014).
Rosso, S. et al. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur. J. Cancer 46, 3351–3357 (2010).
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061–2067 (1999).
Biganzoli, L. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13, e148–e160 (2012).
De Iuliis, F., Salerno, G., Taglieri, L., Lanza, R. & Scarpa, S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori 101, 30–35 (2015).
Crivellari, D. et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann. Oncol. 17, 807–812 (2006).
Toffoli, G. et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin. Cancer Res. 6, 2279–2287 (2000).
Gupta, S. et al. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am. J. Clin. Oncol. 28, 65–69 (2005).
Aapro, M. & Wildiers, H. Triple-negative breast cancer in the older population. Ann. Oncol. 23 (Suppl. 6), vi52–vi55 (2012).
M.C. declares he receives honoraria for consultancy for AbbVie, AstraZeneca, Novartis, Pierre Fabre and Taiho Pharmaceuticals. E.M. declares no competing interests.
About this article
Cite this article
Munzone, E., Colleoni, M. Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol 12, 631–644 (2015). https://doi.org/10.1038/nrclinonc.2015.131
This article is cited by
Human Cell (2022)
Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling
Cell Death & Disease (2021)
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
Breast Cancer Research and Treatment (2021)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
Journal of Translational Medicine (2020)
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
Breast Cancer Research (2020)